CANOPY GROWTH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.7 USD | +3.41% |
|
+2.32% | +89.82% |
| 05-07 | Investors wary of US cannabis ETFs despite recent rally | RE |
| 05-07 | Canopy USA Exercises Options to Acquire Wana, Jetty | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 4.44 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +89.82% | 704M | - | ||
| +44.36% | 6.29B | B- | ||
| -13.52% | 4.55B | C+ | ||
| +10.85% | 3.27B | C | ||
| -6.52% | 3.23B | B- | ||
| -0.71% | 2.56B | - | D+ | |
| +51.14% | 2B | - | ||
| -5.22% | 1.68B | - | - | |
| +1.29% | 1.64B | - | - | |
| +57.69% | 1.6B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WEED Stock
- CGC Stock
- Ratings Canopy Growth Corporation
